NDC 71287-219

TECARTUS

Brexucabtagene Autoleucel

TECARTUS is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Kite Pharma, Inc.. The primary component is Brexucabtagene Autoleucel.

• Product ID: 71287-219_00f83dd6-0f33-4d54-ba07-1be0daad97aa
• NDC: 71287-219
• Product Type: Cellular Therapy
• Proprietary Name: TECARTUS
• Generic Name: Brexucabtagene Autoleucel
• Dosage Form: Suspension
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-07-24
• Marketing Category: BLA / BLA
• Application Number: BLA125703
• Labeler Name: Kite Pharma, Inc.
• Substance Name: BREXUCABTAGENE AUTOLEUCEL
• Active Ingredient Strength: 2000000 1/68mL
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 71287-219-02

1 BAG in 1 PACKAGE (71287-219-02) > 68 mL in 1 BAG (71287-219-01)

• Marketing Start Date: 2020-07-24
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "TECARTUS" or generic name "Brexucabtagene Autoleucel"

NDC	Brand Name	Generic Name
71287-219	TECARTUS	brexucabtagene autoleucel
71287-220	TECARTUS	brexucabtagene autoleucel